Latest News & Features
Refine Search
Big Pharma
In an exclusive interview with LSIPR, Stephen Bennett, partner at Hogan Lovells, talks about the implications of Brexit with a focus on supplementary protection certificates. 25 August 2016
Americas
Pharmaceutical company Pfizer has acquired AstraZeneca’s small molecule anti-infective business. 25 August 2016
Big Pharma
The consequences of the Brexit vote for the life sciences sector will depend on the UK’s relationship with the EU once the negotiations are concluded, as Christina Guazzi and Nina Schäffner of Freshfields Bruckhaus Deringer explain. 25 August 2016
Americas
The Patent Trial and Appeal Board has invalidated claims in two Teva-owned patents covering Copaxone, prompting the Israel-based company to announce its intention to appeal against the ruling. 25 August 2016
Asia
The Japanese government is set to increase intellectual property rights protection for fruits and vegetables, after it discovered that seeds have been exported and produced illegally. 24 August 2016
Americas
Drug prices are increasing significantly in the US due to government regulations, including surrounding patents and market exclusivity, according to a new study. 24 August 2016
Americas
Although recent Federal Circuit decisions on the ‘patent dance’ provide some clarity, the BPCIA still presents difficult and hotly debated issues of interpretation. Stacie Ropka, William Rose and Ryan Hersh of Axinn, Veltrop & Harkrider report. 23 August 2016
Big Pharma
Gilead Sciences has received marketing authorisation from the European Commission for its drug Truvada. 23 August 2016
Americas
AstraZeneca and Eli Lilly have received US Food and Drug Administration fast track designation for the development of a treatment for Alzheimer’s. 23 August 2016
Americas
Pfizer has unveiled plans to acquire US based biopharmaceutical company Medivation for approximately $14 billion. 22 August 2016